Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET).
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02197169 (A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
TypeinterventionalSponsorDNAtrix, Inc.Ran2014 to 2018Enrolled37ConditionsGlioblastoma or GliosarcomaArmsSingle intratumoral injection of DNX-2401, Interferon-gamma
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Chibawanye I Ene *Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2653-281X
Sanjay Singh *Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0042-4658
Thiagarajan VenkataramanImmunology Division, Department of Pathology, Institute for Cell Engineering, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-0921-6345
Lynette M PhillipsDepartment of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0578-2315
James P LongDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5853-5938
Nicholas NavinDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2106-8624
Sujit PrabhuDepartment of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8155-0623
Jeffrey S WeinbergDepartment of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5587-6673
H Benjamin LarmanImmunology Division, Department of Pathology, Institute for Cell Engineering, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0001-7863-196X
Candelaria Gomez-ManzanoThe University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas.ORCID 0000-0002-1259-2133
Juan FueyoThe University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas.ORCID 0000-0001-6941-2335
Frederick F LangDepartment of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3747-873X
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
Center for Clinical and Translational SciencesUM1TR004906 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Maria Eulalia Fernandez, LORNA H. MCNEILL · 2024 to 2026
$16.7M
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for GlioblastomaR01CA247970 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LANG, FREDERICK F · 2020 to 2024
$2.2M
MSC-Derived Exosomes and MicroRNA in Glioma TherapyR01CA214749 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LANG, FREDERICK F · 2018 to 2022
$1.8M
Cancer Prevention and Research Institute of Texas (CPRIT)Cancer Prevention and Research Institute of Texas (CPRIT) RP180684National Cancer Institute (NCI) 1R01CA214749National Cancer Institute (NCI) 1R01CA247970National Cancer Institute (NCI) 2P50CA127001National Cancer Institute (NCI) CCSG P30CA016672-46National Center for Advancing Translational Sciences (NCATS) CCTS UM1TR004906NCATS NIH HHS UM1 TR004906NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA214749NCI NIH HHS R01 CA247970The Baumann Family/Curefest FundThe Broach Foundation for Brain Cancer ResearchThe Dr. Marnie Rose FoundationThe Elias Family FundThe Gene Pennebaker Brain Cancer FundThe Gold Family Memorial FundThe Jim and Pam Harris FundThe Priscila and Jason Hiley FundThe Schneider Memorial Cancer Research FundThe Sorenson FoundationThe Sweet Family Cancer Research FundThe TLC2 Foundation
6 · The paper itself
Abstract
purposeThe aim of the study is to evaluate the combination of intratumoral Delta-24-RGD and subcutaneous interferon gamma (IFNγ) in patients with high-grade glioma (HGG), based on the rationale that augmenting the immune response with IFNγ will increase the efficacy of Delta-24-RGD treatment. PATIENTS AND
methodsIn this phase Ib, multicenter, randomized trial (NCT02197169), we evaluated the combination of intratumorally injected Delta-24-RGD with subcutaneously administered IFNγ, a potent activator of Th1 CD8+ cell immune response, in 37 patients with recurrent HGG and investigated systemic immune correlates of long-term survival. Twenty-seven patients were randomized 2:1 into two cohorts: Delta-24-RGD (via standard biopsy needle) with IFNγ or Delta-24-RGD alone (via standard biopsy needle). In an expansion cohort, 10 patients received intratumorally injected Delta-24-RGD via the MEMS cannula.
resultsAlthough the addition of IFNγ to Delta-24-RGD did not significantly increase the percentage of long-term survivors (LTS) compared with Delta-24-RGD alone, the IFNγ cohort had the longest-surviving patients [overall survival (OS) 44.2, 23.7, 20.6, and 20.1 months]. Post hoc analysis of plasma and peripheral blood mononuclear cells using viral Phage Immunoprecipitation Sequencing Antibody Reactome profiling of viral epitopes (VirScan) and single-cell RNA sequencing revealed that levels of circulating anti-adenovirus-specific IgG and CD8+ natural killer T (NKT)-like cells 2 months after treatment with Delta-24-RGD distinguished LTS from short-term survivors.
conclusionsImmunologic fitness, assessed by an anti-adenoviral-specific antibody response and higher levels of activated CD8+ NKT-like cells after Delta-24-RGD treatment, may have utility as an early surrogate of a robust systemic immune response that correlates with long-term survival.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). · full record | OpenQuestion